



Sinead Cuffe

Contact

Sinead Cuffe

Publications (4)

Molina-Vila M, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Palmero R, Massutí B, Stahel R, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. *J Thorac Oncol* 2019; 15:416-425.

O'Brien O, Gray S, Jörger M, Jochum W, Fabre A, Cuffe S, Nicholson S, Leonard N, Geoghegan O, O'Brien C, Wright M, Finn S. Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. *Diagnostics (Basel)* 2019; 9

Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med* 2017; 5:435-444.

Jörger M, Finn S, Cuffe S, Byrne A, Gray S. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. *Expert Opin Ther Targets* 2016; 20:1339-1356.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch